marți, 25 martie 2014
joi, 13 martie 2014
Type 1 diabetes: Gut microbiota networks may influence autoimmune processes
http://www.sciencedaily.com/releases/2014/03/140312082530.htm
Crohn disease - microbiata direct link
http://www.sciencedaily.com/releases/2014/03/140312132617.htm
Immune system's redesigned role in fighting cancerous tumors
Rsearchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.
The study's findings, published in the journal Cancer Research, are the first to use
these combined agents as an immune stimulator and may have the potential to kill
cancerous cells in solid tumors, including some of the most aggressive cancers that
form in the lung and pancreas. Investigators hope to bring this science to early phase
clinical trials in coming months.
these combined agents as an immune stimulator and may have the potential to kill
cancerous cells in solid tumors, including some of the most aggressive cancers that
form in the lung and pancreas. Investigators hope to bring this science to early phase
clinical trials in coming months.
"Instead of administering a cancer vaccine to destroy tumors, we hope to modify the
immune system to allow the patient's own tumor to act as a cancer vaccine," said
Hyung Lae Kim, MD, co-medical director of the Urologic Oncology Program and lead
author of the study. "This approach differs from traditional methods, where the
immune system is stimulated by administering a vaccine. Instead, we administer a combination therapy to allow
immune cells, which are capable of killing tumors, to see tumors that were previously invisible to the immune
system."
immune system to allow the patient's own tumor to act as a cancer vaccine," said
Hyung Lae Kim, MD, co-medical director of the Urologic Oncology Program and lead
author of the study. "This approach differs from traditional methods, where the
immune system is stimulated by administering a vaccine. Instead, we administer a combination therapy to allow
immune cells, which are capable of killing tumors, to see tumors that were previously invisible to the immune
system."
When an immune system is working properly, diseased cells are captured and killed. However, cancerous
tumors are formed when the immune system is unable to remove these diseased cells. Using an "mTOR
inhibitor," which regulates cellular metabolism, and a CD4 antibody, which helps to initiate an immune response,
researchers increased the immune system's "memory" and ability to recognize and fight off tumors.
"With our approach, investigators simply combine an mTOR inhibitor and CD4 antibody to create an
immunotherapy treatment, requiring no surgery and a drug with virtually no shelf life," said Robert Figlin, MD,
deputy director of the Samuel Oschin Comprehensive Cancer Institute and the Steven Spielberg Family Chair in
Hematology-Oncology. "This broad implication is in contrast to a more traditional vaccine-based approach, which
requires a specialist to surgically remove tumor samples from a patient's body then create a personalized
vaccine approach for one specific patient."
immunotherapy treatment, requiring no surgery and a drug with virtually no shelf life," said Robert Figlin, MD,
deputy director of the Samuel Oschin Comprehensive Cancer Institute and the Steven Spielberg Family Chair in
Hematology-Oncology. "This broad implication is in contrast to a more traditional vaccine-based approach, which
requires a specialist to surgically remove tumor samples from a patient's body then create a personalized
vaccine approach for one specific patient."
The combination of a CD4 antibody with an mTOR inhibitor may enhance immune memory and eradicate solid
tumors. Additional research is being done to better understand how the drugs work and develop optimal
strategies for applications in patients.
tumors. Additional research is being done to better understand how the drugs work and develop optimal
strategies for applications in patients.
Yanping Wang, MD, project coordinator in the Kim Laboratory at Cedars-Sinai, and Tim Sparwasser, MD, from
the Institute of Infection Immunology at TWINCORE, were involved in the study.
the Institute of Infection Immunology at TWINCORE, were involved in the study.
Citation: Cancer Research. 2014 February: Foxp3+ T cells inhibit antitumor immune memory modulated by
mTOR inhibition.
mTOR inhibition.
Story Source:
The above story is based on materials provided by Cedars-Sinai Medical Center.Note: Materials may be
edited for content and length.
edited for content and length.
Journal Reference:
- Y. Wang, T. Sparwasser, R. Figlin, H. L. Kim. Foxp3 T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Research, 2014; DOI: 10.1158/0008-5472.CAN-13-2928
Source:
http://www.sciencedaily.com/releases/2014/03/140312103145.htm
marți, 11 martie 2014
Abonați-vă la:
Postări (Atom)
Ce cauti tu, cu ciubotele tale, in sufletul meu?